We are live on ! Find out more
AURA icon

Aura Biosciences
AURA

57 hedge funds and large institutions have $233M invested in Aura Biosciences in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

100% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 12

16% more funds holding

Funds holding: 49 → 57 (+8)

0.27% more ownership

Funds ownership: 66.06% → 66.32% (+0.27%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

7% less capital invested

Capital invested by funds: $250M → $233M (-$17.4M)

Holders
57
Holders Change
+8
Holders Change %
+16.33%
% of All Funds
0.91%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
24
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$6M
2
Citigroup
Citigroup
New York
+$3.85M
3
BlackRock
BlackRock
New York
+$2.89M
4
EAM
Eventide Asset Management
Massachusetts
+$2.85M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.92M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$4.3M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.86M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.44M
4
MIM
Monashee Investment Management
Massachusetts
-$1.38M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$297K
Name Holding Trade Value Shares
Change 		Change in
Stake
MCMC
1
Matrix Capital Management Company
New Hampshire
$49.8M – – –
MVM
2
Medicxi Ventures Management
Jersey
$28.2M – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$25.1M +$6M +577,261 +27%
EAM
4
Eventide Asset Management
Massachusetts
$23.4M +$2.85M +274,462 +12%
Citadel Advisors
5
Citadel Advisors
Florida
$23.2M -$2.44M -234,832 -9%
BlackRock
6
BlackRock
New York
$12.4M +$2.89M +277,973 +26%
Vanguard Group
7
Vanguard Group
Pennsylvania
$9.73M +$1.92M +185,007 +21%
RSCM
8
Rock Springs Capital Management
Maryland
$9.46M – – –
NCM
9
Nantahala Capital Management
Connecticut
$7.83M +$464K +44,695 +6%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$6.59M -$297K -28,610 -4%
RCM
11
Regency Capital Management
Hawaii
$5.05M -$110K -10,611 -2%
Citigroup
12
Citigroup
New York
$4.79M +$3.85M +370,338 +254%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$4.25M +$1.64M +157,435 +52%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$3.31M -$3.86M -371,550 -51%
State Street
15
State Street
Massachusetts
$3.23M +$393K +37,865 +12%
DCMIC
16
Decheng Capital Management III (Cayman)
Cayman Islands
$2.72M – – –
Goldman Sachs
17
Goldman Sachs
New York
$2.68M +$861K +82,918 +40%
Northern Trust
18
Northern Trust
Illinois
$1.81M +$536K +51,606 +36%
LFCM
19
Long Focus Capital Management
Puerto Rico
$1.59M +$1.78M +171,377 New
Morgan Stanley
20
Morgan Stanley
New York
$674K +$83K +7,990 +12%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$600K +$151K +14,563 +29%
Charles Schwab
22
Charles Schwab
California
$588K +$162K +15,606 +33%
N
23
Nuveen
North Carolina
$504K +$54.5K +5,252 +11%
TD Asset Management
24
TD Asset Management
Ontario, Canada
$501K – – –
Manulife (Manufacturers Life Insurance)
25
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$482K +$97.7K +9,406 +22%
1
2 3

AURA Hedge Fund Activity: Q1 2023 in Review

57 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q1 2023, worth a combined $233M — down 7% from $250M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new AURA positions and 6 closed out — a net gain of 8 holders — while 24 added to existing stakes and 12 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $6M. The largest seller was Artal Group, exiting entirely with an estimated $4.3M sold.

  • 57 institutional investors held Aura Biosciences (AURA) as of Q1 2023, up from 49 in Q4 2022.
  • Funds reported $233M of Aura Biosciences stock for Q1 2023, down 7% quarter-over-quarter.
  • 14 funds opened new Aura Biosciences positions in Q1 2023 and 6 closed out, a net change of +8 holders.
  • The largest Aura Biosciences buyer in Q1 2023 was Adage Capital Partners, an estimated $6M added.
  • The largest Aura Biosciences seller in Q1 2023 was Artal Group, an estimated $4.3M sold.

Based on aggregated 13F filings for Q1 2023.